The in vitro effects of niacin on platelet biomarkers in human volunteers

Victor Serebruany, Alex Malinin, Daniel Aradi, Wiktor Kuliczkowski, Nicholas B. Norgard, William E. Boden

Research output: Contribution to journalArticle

Abstract

Niacin is a natural pyridine derivative, proven to favorably modulate the blood lipid profile by increasing levels of high-density lipoprotein (HDL) cholesterol, and by reducing total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and Lp (a) lipoprotein concentrations. Considering that platelet activity is important in predicting vascular outcomes, and that HDL heavily constitutes platelet cellular membranes, we sought to evaluate the effect of niacin on human platelet activity indices. The blood obtained from 30 aspirin-naïve volunteers was preincubated with escalating concentrations of niacin in vitro. Platelet tests included whole blood and plasma aggregometry, rapid cartridge-based analyser, expression of major surface receptors by flow cytometry, and plasma prostaglandins by ELISA. Preincubation of blood with niacin at 0.3, 1.0 and 3.0 mM resulted in significant inhibition of maximal adenosine diphosphate (ADP)- (p=0.03), and collagen-induced platelet aggregation (p=0.01), and reduced activity by VerifyNow™ (p=0.007) bedside analyser. Surface platelet PAR-1 (MoAb WEDE-15; p=0.04), and vitronectin (CD51/CD61; p=0.02) receptors were up-regulated. Niacin was associated with a two- to three-fold increase of thromboxane B2, prostaglandins D2, and E2. Formation of platelet-monocyte microparticles (CD14+CD151), and expression of PECAM-1 (CD31), thrombospondin (CD36), GP IIb/IIIa (CD41a) antigen, and activity with MoAb PAC-1, GPIb (CD42b), P-selectin (CD62p), LAMP-3 (CD63), LAMP-1 (CD107a), CD40-ligand (CD154), GP37 (CD165), were not affected by niacin, suggesting no effect on prostacyclin release. In conclusion, niacin in vitro affects platelet activity by mildly inhibiting aggregation, and stimulating significant prostaglandin release, with mostly intact major platelet receptor expression. The effect of niacin is unique, differs from other known antiplatelet agents, and suggests potential opportunities for therapeutic combination, particularly in patients with low levels of HDL-C. These preliminary data, while intriguing, require confirmation in subjects receiving orally dosed extended-release niacin in order to determine whether these findings are clinically relevant.

Original languageEnglish (US)
Pages (from-to)311-317
Number of pages7
JournalThrombosis and Haemostasis
Volume104
Issue number2
DOIs
StatePublished - Aug 2010

Fingerprint

Niacin
Volunteers
Blood Platelets
Biomarkers
HDL Lipoproteins
Prostaglandins
Platelet Membrane Glycoprotein IIb
CD31 Antigens
Thrombospondins
Vitronectin
In Vitro Techniques
Prostaglandin D2
Thromboxane B2
CD40 Ligand
P-Selectin
Platelet Aggregation Inhibitors
Epoprostenol
Platelet Aggregation
Dinoprostone
Human Activities

Keywords

  • In vitro
  • Lipids
  • Niacin
  • Platelets

ASJC Scopus subject areas

  • Hematology

Cite this

Serebruany, V., Malinin, A., Aradi, D., Kuliczkowski, W., Norgard, N. B., & Boden, W. E. (2010). The in vitro effects of niacin on platelet biomarkers in human volunteers. Thrombosis and Haemostasis, 104(2), 311-317. https://doi.org/10.1160/TH10-01-0015

The in vitro effects of niacin on platelet biomarkers in human volunteers. / Serebruany, Victor; Malinin, Alex; Aradi, Daniel; Kuliczkowski, Wiktor; Norgard, Nicholas B.; Boden, William E.

In: Thrombosis and Haemostasis, Vol. 104, No. 2, 08.2010, p. 311-317.

Research output: Contribution to journalArticle

Serebruany, V, Malinin, A, Aradi, D, Kuliczkowski, W, Norgard, NB & Boden, WE 2010, 'The in vitro effects of niacin on platelet biomarkers in human volunteers', Thrombosis and Haemostasis, vol. 104, no. 2, pp. 311-317. https://doi.org/10.1160/TH10-01-0015
Serebruany V, Malinin A, Aradi D, Kuliczkowski W, Norgard NB, Boden WE. The in vitro effects of niacin on platelet biomarkers in human volunteers. Thrombosis and Haemostasis. 2010 Aug;104(2):311-317. https://doi.org/10.1160/TH10-01-0015
Serebruany, Victor ; Malinin, Alex ; Aradi, Daniel ; Kuliczkowski, Wiktor ; Norgard, Nicholas B. ; Boden, William E. / The in vitro effects of niacin on platelet biomarkers in human volunteers. In: Thrombosis and Haemostasis. 2010 ; Vol. 104, No. 2. pp. 311-317.
@article{ee032d52cf57405eb44e1bbf37d1866f,
title = "The in vitro effects of niacin on platelet biomarkers in human volunteers",
abstract = "Niacin is a natural pyridine derivative, proven to favorably modulate the blood lipid profile by increasing levels of high-density lipoprotein (HDL) cholesterol, and by reducing total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and Lp (a) lipoprotein concentrations. Considering that platelet activity is important in predicting vascular outcomes, and that HDL heavily constitutes platelet cellular membranes, we sought to evaluate the effect of niacin on human platelet activity indices. The blood obtained from 30 aspirin-na{\"i}ve volunteers was preincubated with escalating concentrations of niacin in vitro. Platelet tests included whole blood and plasma aggregometry, rapid cartridge-based analyser, expression of major surface receptors by flow cytometry, and plasma prostaglandins by ELISA. Preincubation of blood with niacin at 0.3, 1.0 and 3.0 mM resulted in significant inhibition of maximal adenosine diphosphate (ADP)- (p=0.03), and collagen-induced platelet aggregation (p=0.01), and reduced activity by VerifyNow™ (p=0.007) bedside analyser. Surface platelet PAR-1 (MoAb WEDE-15; p=0.04), and vitronectin (CD51/CD61; p=0.02) receptors were up-regulated. Niacin was associated with a two- to three-fold increase of thromboxane B2, prostaglandins D2, and E2. Formation of platelet-monocyte microparticles (CD14+CD151), and expression of PECAM-1 (CD31), thrombospondin (CD36), GP IIb/IIIa (CD41a) antigen, and activity with MoAb PAC-1, GPIb (CD42b), P-selectin (CD62p), LAMP-3 (CD63), LAMP-1 (CD107a), CD40-ligand (CD154), GP37 (CD165), were not affected by niacin, suggesting no effect on prostacyclin release. In conclusion, niacin in vitro affects platelet activity by mildly inhibiting aggregation, and stimulating significant prostaglandin release, with mostly intact major platelet receptor expression. The effect of niacin is unique, differs from other known antiplatelet agents, and suggests potential opportunities for therapeutic combination, particularly in patients with low levels of HDL-C. These preliminary data, while intriguing, require confirmation in subjects receiving orally dosed extended-release niacin in order to determine whether these findings are clinically relevant.",
keywords = "In vitro, Lipids, Niacin, Platelets",
author = "Victor Serebruany and Alex Malinin and Daniel Aradi and Wiktor Kuliczkowski and Norgard, {Nicholas B.} and Boden, {William E.}",
year = "2010",
month = "8",
doi = "10.1160/TH10-01-0015",
language = "English (US)",
volume = "104",
pages = "311--317",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - The in vitro effects of niacin on platelet biomarkers in human volunteers

AU - Serebruany, Victor

AU - Malinin, Alex

AU - Aradi, Daniel

AU - Kuliczkowski, Wiktor

AU - Norgard, Nicholas B.

AU - Boden, William E.

PY - 2010/8

Y1 - 2010/8

N2 - Niacin is a natural pyridine derivative, proven to favorably modulate the blood lipid profile by increasing levels of high-density lipoprotein (HDL) cholesterol, and by reducing total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and Lp (a) lipoprotein concentrations. Considering that platelet activity is important in predicting vascular outcomes, and that HDL heavily constitutes platelet cellular membranes, we sought to evaluate the effect of niacin on human platelet activity indices. The blood obtained from 30 aspirin-naïve volunteers was preincubated with escalating concentrations of niacin in vitro. Platelet tests included whole blood and plasma aggregometry, rapid cartridge-based analyser, expression of major surface receptors by flow cytometry, and plasma prostaglandins by ELISA. Preincubation of blood with niacin at 0.3, 1.0 and 3.0 mM resulted in significant inhibition of maximal adenosine diphosphate (ADP)- (p=0.03), and collagen-induced platelet aggregation (p=0.01), and reduced activity by VerifyNow™ (p=0.007) bedside analyser. Surface platelet PAR-1 (MoAb WEDE-15; p=0.04), and vitronectin (CD51/CD61; p=0.02) receptors were up-regulated. Niacin was associated with a two- to three-fold increase of thromboxane B2, prostaglandins D2, and E2. Formation of platelet-monocyte microparticles (CD14+CD151), and expression of PECAM-1 (CD31), thrombospondin (CD36), GP IIb/IIIa (CD41a) antigen, and activity with MoAb PAC-1, GPIb (CD42b), P-selectin (CD62p), LAMP-3 (CD63), LAMP-1 (CD107a), CD40-ligand (CD154), GP37 (CD165), were not affected by niacin, suggesting no effect on prostacyclin release. In conclusion, niacin in vitro affects platelet activity by mildly inhibiting aggregation, and stimulating significant prostaglandin release, with mostly intact major platelet receptor expression. The effect of niacin is unique, differs from other known antiplatelet agents, and suggests potential opportunities for therapeutic combination, particularly in patients with low levels of HDL-C. These preliminary data, while intriguing, require confirmation in subjects receiving orally dosed extended-release niacin in order to determine whether these findings are clinically relevant.

AB - Niacin is a natural pyridine derivative, proven to favorably modulate the blood lipid profile by increasing levels of high-density lipoprotein (HDL) cholesterol, and by reducing total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and Lp (a) lipoprotein concentrations. Considering that platelet activity is important in predicting vascular outcomes, and that HDL heavily constitutes platelet cellular membranes, we sought to evaluate the effect of niacin on human platelet activity indices. The blood obtained from 30 aspirin-naïve volunteers was preincubated with escalating concentrations of niacin in vitro. Platelet tests included whole blood and plasma aggregometry, rapid cartridge-based analyser, expression of major surface receptors by flow cytometry, and plasma prostaglandins by ELISA. Preincubation of blood with niacin at 0.3, 1.0 and 3.0 mM resulted in significant inhibition of maximal adenosine diphosphate (ADP)- (p=0.03), and collagen-induced platelet aggregation (p=0.01), and reduced activity by VerifyNow™ (p=0.007) bedside analyser. Surface platelet PAR-1 (MoAb WEDE-15; p=0.04), and vitronectin (CD51/CD61; p=0.02) receptors were up-regulated. Niacin was associated with a two- to three-fold increase of thromboxane B2, prostaglandins D2, and E2. Formation of platelet-monocyte microparticles (CD14+CD151), and expression of PECAM-1 (CD31), thrombospondin (CD36), GP IIb/IIIa (CD41a) antigen, and activity with MoAb PAC-1, GPIb (CD42b), P-selectin (CD62p), LAMP-3 (CD63), LAMP-1 (CD107a), CD40-ligand (CD154), GP37 (CD165), were not affected by niacin, suggesting no effect on prostacyclin release. In conclusion, niacin in vitro affects platelet activity by mildly inhibiting aggregation, and stimulating significant prostaglandin release, with mostly intact major platelet receptor expression. The effect of niacin is unique, differs from other known antiplatelet agents, and suggests potential opportunities for therapeutic combination, particularly in patients with low levels of HDL-C. These preliminary data, while intriguing, require confirmation in subjects receiving orally dosed extended-release niacin in order to determine whether these findings are clinically relevant.

KW - In vitro

KW - Lipids

KW - Niacin

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=77955454241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955454241&partnerID=8YFLogxK

U2 - 10.1160/TH10-01-0015

DO - 10.1160/TH10-01-0015

M3 - Article

C2 - 20539903

AN - SCOPUS:77955454241

VL - 104

SP - 311

EP - 317

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -